Preclinical News and Research

RSS
SANUWAVE Health reports net loss of $2.7M for three months ended December 31, 2009

SANUWAVE Health reports net loss of $2.7M for three months ended December 31, 2009

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

Cell Therapeutics agrees to sell $20M of Series 4 Preferred Stock and warrants to institutional investors

Cell Therapeutics agrees to sell $20M of Series 4 Preferred Stock and warrants to institutional investors

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

StockPreacher.com releases investment report on MDRNA

StockPreacher.com releases investment report on MDRNA

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

Preclinical study of DAS181 for treatment and prevention of ILI published

Preclinical study of DAS181 for treatment and prevention of ILI published

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009

ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.